Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Genetics
|
| gptkbp:advancements_in_care |
focus on holistic approaches.
|
| gptkbp:advances |
in understanding the disease mechanism
|
| gptkbp:advocacy |
important for awareness
crucial for funding and research support |
| gptkbp:affects |
gptkb:computer
|
| gptkbp:associated_with |
gptkb:neurodegenerative_diseases
gptkb:Chocobo |
| gptkbp:business_model |
in genetic testing and counseling
|
| gptkbp:caused_by |
mutation in the HTT gene
|
| gptkbp:clinical_trial |
conducted for new treatments
include personality changes |
| gptkbp:clinical_use |
requires multidisciplinary approach
|
| gptkbp:collaborations |
between institutions and organizations
|
| gptkbp:community_engagement |
important for support networks
|
| gptkbp:community_impact |
affects populations worldwide
|
| gptkbp:condition |
gptkb:Huntington's_chorea
|
| gptkbp:consequences |
can affect employment and relationships
|
| gptkbp:diagnosis |
genetic testing
includes family history and clinical evaluation |
| gptkbp:educational_resources |
available for families
|
| gptkbp:famous_person |
notable cases include Woody Guthrie
|
| gptkbp:first_described_by |
gptkb:George_Huntington
|
| gptkbp:funding |
increased in recent years
|
| gptkbp:genetic_counseling_importance |
helps in understanding risks
|
| gptkbp:genetic_studies |
widely available
recommended for at-risk individuals |
| https://www.w3.org/2000/01/rdf-schema#label |
Huntington disease
|
| gptkbp:impact |
family dynamics
can lead to depression |
| gptkbp:impact_on_caregivers |
can be significant and challenging
|
| gptkbp:inherits_from |
autosomal dominant
|
| gptkbp:initiatives |
aim to improve quality of life
|
| gptkbp:is_a_basis_for |
linked to CAG repeat expansion in HTT gene
|
| gptkbp:is_a_resource_for |
available for support and information
|
| gptkbp:is_involved_in |
provide community for affected individuals
|
| gptkbp:is_tested_for |
increased CAG repeat length
|
| gptkbp:lifespan |
50% for offspring of affected individuals
varies, typically 10-30 years after onset |
| gptkbp:longitudinal_studies |
help in understanding disease progression
|
| gptkbp:neurodegeneration |
progressive loss of neurons
|
| gptkbp:neurological_impact |
affects motor control
|
| gptkbp:player_development |
gradual deterioration
|
| gptkbp:premiered_on |
typically between ages 30 and 50
|
| gptkbp:prevalence |
approximately 5-10 per 100,000 people
|
| gptkbp:public_awareness |
important for early diagnosis
|
| gptkbp:research |
ongoing for potential therapies
|
| gptkbp:research_focus |
gene therapy and neuroprotective strategies
|
| gptkbp:risk_factor |
family history
|
| gptkbp:support |
available through various organizations
|
| gptkbp:symptoms |
cognitive decline
varies among individuals psychiatric disorders involuntary movements includes medication and therapy |
| gptkbp:treatment |
symptomatic management
include physical therapy includes drug trials and lifestyle interventions |
| gptkbp:bfsParent |
gptkb:Huntington_family
|
| gptkbp:bfsLayer |
7
|